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dergoing thrombolysis between 2005 and 2013. Patients were allocated
to the low-ﬁbrinogen group if their ﬁbrinogen level was <1.5 g/L during
treatment or to the high-ﬁbrinogen group. Demographics, bleeding compli-
cations, and technical and clinical success were statistically analyzed between
the groups.
Results: A total of 49 patients (22 arterial and 27 venous), with a
mean age of 52.0 6 18.4 years, were included. Sixteen patients were allo-
cated to the low-ﬁbrinogen group and 26 to the high-ﬁbrinogen group
(ﬁbrinogen levels were not measured in seven patients; none of these pa-
tients had any bleeding complications). Patients were signiﬁcantly younger
(41.1 6 17.3 vs 56 6 15.7 years; P ¼ .006) and had a proportionately
higher number of venous occlusive events (87.5% vs 42.6%; P ¼ .004) in
the low-ﬁbrinogen group compared with the high-ﬁbrinogen group. Other
baseline characteristics, including gender, extremities affected, prothrom-
botic risk factors, contraindications to thrombolysis, baseline ﬁbrinogen, in-
ternational normalized ratio, partial thromboplastin time, and platelets were
similar between the groups. The low-ﬁbrinogen group used a larger total
dose of tissue plasminogen activator (tPA; 40.7 6 24.6 mg vs 21.9 6
10.5 mg, P ¼ .009) and had longer duration of tPA infusion (26.8 6
12.9 hours vs 16.9 6 6.6 hours; P ¼ .010). The rates of major and minor
bleeding were not signiﬁcantly different between the low-ﬁbrinogen vs
high-ﬁbrinogen groups (2 vs 0 cases of major bleed, respectively, P ¼
.139; 1 vs 4 cases of minor bleed, respectively; P ¼ .633). Secondary out-
comes including technical and clinical success rate, in-hospital mortality,
hospital length of stay, and secondary procedures were similar between
groups.
Conclusions: A ﬁbrinogen level of <1.5 g/L during thrombolysis
was not associated with an increased risk of bleeding complications; this
was despite a larger total dose and longer duration of tPA infusion used.
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Objectives: The aim of this study was to determine the length of stay
in our cohort of patients who underwent endovascular aortic aneurysm
repair (EVAR) and to identify patient characteristics suitable for same-day
or short-term discharge. We also conducted a review of the literature exam-
ining the evidence for safety and efﬁcacy of ambulatory and short-stay
EVAR.
Methods: A retrospective analysis of consecutive patients who under-
went elective EVAR by three vascular surgeons in our institution since April
2011 until March 2013 was conducted. Patient demographics, comorbid-
ities, aneurysm anatomy, length of stay, and complications were analyzed.
The literature review identiﬁed four articles on outpatient or short-stay
EVAR.
Results: During the study period, 162 patients underwent elective
EVAR and 138 were included in the analysis (24 patients were excluded
due to insufﬁcient data, aneurysm rupture, or thoracic endovascular aortic
repair). Seven patients (5.1%) were discharged the same day (SD) of proce-
dure, 81 patients (58.7%) were discharged on postoperative day (POD) 1,
and 50 patients (36.2%) were discharged on POD2 or longer (standard
group). The standard group was signiﬁcantly older (78.44 6 8.32 years)
than the POD1 and SD groups (72.9 6 8.41 and 71.3 6 11.2, respectively;
P ¼ .0004). Mean aneurysm size was 54 6 2.98 mm for the SD group, 57
6 9.57 mm for POD1 group, and 59 6 11.29 mm for the standard group.
The 30-day mortality was zero in all three groups. The procedures in all pa-
tients (100%) in the SD group, 70 patients (86%) discharged on POD1, and
26 patients (52%) in the standard group were performed fully percutane-
ously (P < .0001). Percutaneous arterioplasty device failure, thus necessi-
tating a femoral cutdown, occurred in eight patients (9.8%) in the POD1
group and in eight patients (16%) in the standard group (P ¼ .33). All
groups had similar baseline comorbidities (hypertension, hyperlipidemia,
chronic renal failure, diabetes mellitus, chronic obstructive pulmonary dis-
ease; not signiﬁcant [NS]). Ninety-six percent of all procedures were per-
formed with a spinal anesthetic. Reasons for prolonged hospital stay
included urinary retention, postimplantation syndrome, symptomatic aneu-
rysm, or insertion of aortouniiliac stent with cross-femoral bypass. Readmis-
sion to the hospital #30 days of EVAR was zero in SD group patients, fourpatients (5%) in the POD1 group, and three patients (6%) in the standard
group (NS). The 30-day complication rate was 5% in the POD1 group
and 20% in the standard group (P ¼ .0069).
Conclusions: Discharging patients the SD overnight after elective
EVAR is feasible and safe in patients with acceptable medical risk, good
baseline functional capacity, and who have undergone uncomplicated aneu-
rysm repair. The literature shows that discharge #24 hours post-EVAR is
feasible in one-third of patients. Future prospective studies, including cost
analysis, will be undertaken to validate these encouraging data.
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Objectives: Over the last decade the use of endografts for the repair of
abdominal aortic aneurysm has steadily increased. Despite improvements in
endograft device technology, we continue to see complications that require
reintervention. Here we present a systematic literature review of the indica-
tion for late endograft explants as well as a small case series of late endograft
explants.
Methods: We conducted a retrospective case series of three endograft
explants at a single center during a 3-year period. Additionally, systematic
literature review of the PubMed database with the search terms (explant
or late conversion) and (endograft or EVAR) was undertaken, with interest
in indications for explantation and overall outcome after explantation.
Results: We present three cases of late surgical conversion after endo-
vascular aneurysm repair (EVAR) repair of abdominal aortic aneurysm: (1)
an 88-year old woman with a late type I endoleak and proximal graft migra-
tion 18 months post-EVAR; (2) a 66-year-old man with a methicillin-resis-
tant Staphylococcus aureus infected endograft 2 years post-EVAR; and (3) a
64-year-old man with an acute occlusion of his endograft 6 years post-
EVAR. A systematic review of the literature revealed 478 reported cases
of late endograft explantation. The predominant indication for explantation
was endoleak, representing 58% (n ¼ 277) of endograft explants (type I,
106; type II, 59; type III, 41; type V, 5; multiple endoleaks, 5; undeﬁned,
62). Other indications for explant included infection 21% (n ¼ 100), occlu-
sion 5.2% (n ¼ 25), aortoenteric ﬁstula 2.7% (n ¼ 13) and claudication 1%
(n ¼ 5). Of the reported cases, 11% presented as ruptured AAA. Where re-
ported, elective 30-day mortality ranged from 0% to 10%, and nonelective
30-day mortality ranged from 19% to 53%.
Conclusions: The primary reported indication for late open conver-
sion was type I endoleaks, followed closely by infection. Although these
can be technically challenging procedures, elective open conversion comes
with a low mortality rate relative to urgent procedures. Nonadherence to
manufacturers’ recommendation for endograft use and late aortic remodel-
ing could explain large number of endoleaks noted.
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Objectives: Prosthetic vascular infection is an uncommon but devas-
tating event, occurring after w <0.1% to 5% of operations and developing
months to years after the initial implantation. Similarly, mycotic aneurysms
occur rarely but still carry a 25% mortality rate. Both entities may be chal-
lenging to eradicate. Therapeutic options are limited. Complex surgical pro-
cedures with wide debridement are often required, and outcomes are
variable. This study evaluated the use of in situ reconstruction with
custom-made bovine pericardial grafts as an alternative to in situ autologous
vein graft, prosthetic grafts, and cryopreserved arterial homografts for the
treatment of aortic graft infections and infected aortic aneurysms.
Methods: Between 2009 and 2014, eight patients (50% men; age
range, 51-84 years) with prosthetic graft infection (n ¼ 6) or thoracoabdo-
minal mycotic aneurysm (n ¼ 2) were treated with complete prosthesis or
aneurysm resection, together with wide local debridement and arterial
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cardial sheets.
Results: Patients selected for bovine pericardial tube grafting had pre-
viously documented infection that occurred between 1 month and 6 years
after initial prosthesis implantation. One patient had recurrent graft reinfec-
tion, which was attributed to a recurrent aortoduodenal ﬁstula. The patient
eventually underwent a second pericardial tube graft with resolution of the
infection. Follow-up imaging did not reveal any signs of infection in the
other patients. The overall 30-day perioperative mortality rate was 12.5%
(n ¼ 1) and occurred in relation to severe underlying pulmonary disease
and not as a consequence of graft failure.
Conclusions: Pericardial tube grafting is a potential alternative to
conventional surgical methods for the treatment of aortic graft infections
and infected aortic aneurysm. Further investigation of long-term outcomes
is required.
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Objectives: Surgical dogma holds that chemotherapy increases the
risk of aneurysm growth and rupture. We sought to determine the effect
of cytotoxic chemotherapy on the growth of aortic aneurysms.Methods: All patients undergoing chemotherapy for malignancy with
coexisting aortic aneurysms at our institution between 2000 and 2011 were
identiﬁed. A review of electronic medical records and a re-review of serial
cross-sectional imaging was performed. An additional cohort of patients un-
dergoing aneurysm surveillance during the same period was identiﬁed, and
demographic and anatomic variables were collected. Planned analysis
included descriptive analysis, change in aneurysm diameter over time, and
association of growth or need for intervention with type of chemotherapy
and type of malignancy.
Results: Between 2000 and 2010, there were 125 patients at our
institution with a concurrent diagnosis of aortic aneurysm and malignancy
requiring cytotoxic chemotherapy. Cross-sectional imaging was available
for 91 of the 125 patients. The predominant malignancy type was lung can-
cer in 34 of 91 patients (38%), followed by lymphoma in 21 (23%) and colo-
rectal cancer in 10 (11%). The aneurysms in 53 patients (58%) were
infrarenal. Most patients were treated with more than one class of chemo-
therapeutic agent over 267 days (interquartile range [IQR], 144-
469 days), the majority having at least one cycle of alkylating agents (73
of 91), in addition to antimetabolites (42 of 91) and plant alkyloids/terpe-
noids (40 of 91). Chemotherapy regimens included steroids in 84 patients
(92%). The baseline aneurysm diameter for patients on and not on chemo-
therapeutic agents was 41.4 mm (IQR, 34.9-51.3 mm) and 46.0 mm (IQR,
40-52 mm), respectively. Aneurysm repair during chemotherapy occurred
in eight of 91 patients (9%), but only two required urgent repair due to
aneurysm rupture. The annual rate of aneurysm growth for patients on
and not on chemotherapy was similar (2.3 mm/y vs 2.4 mm/y; P ¼ .69).
Conclusions: In 91 patients over 10 years at our institution, chemo-
therapy did not increase aneurysm growth compared with patients not un-
dergoing treatment for malignancy.
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